Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2017

01-12-2017 | Original article

Preemptive kidney transplantation: a propensity score matched cohort study

Authors: Masayoshi Okumi, Yasuyuki Sato, Kohei Unagami, Toshihito Hirai, Hideki Ishida, Kazunari Tanabe, The Japan Academic Consortium of Kidney Transplantation (JACK)

Published in: Clinical and Experimental Nephrology | Issue 6/2017

Login to get access

Abstract

Background

The reasons for improved outcomes associated with preemptive kidney transplantation (PKT) are incompletely understood, and post-transplant complications have been scarcely investigated.

Methods

We evaluated the outcomes of PKT in both unmatched (n = 1060) and propensity score matched cohorts (n = 186) of adults who underwent living kidney transplant between 2000 and 2014. Outcomes were estimated glomerular filtration rate (eGFR), biopsy-proven rejection, cytomegalovirus (CMV) infection, post-transplant diabetes mellitus (PTDM), cardiovascular disease (CVD), graft failure (non-censored for death), and malignancy. Primary endpoint was post-transplant renal function assessed with eGFR.

Results

A total of 95 patients (9.0 %) underwent PKT. The 2-week mean eGFR after transplant was comparable between the matched PKT and non-PKT groups (45.2 vs. 46.5 mL/min/1.73 m2, respectively, P = 0.56). Sensitivity analysis using various formulas did not change the results. PKT was not superior to non-PKT in reducing the risk of biopsy-proven rejection, CMV, PTDM, and malignancy, regardless of matching. The risk of graft failure and CVD was significantly reduced in the unmatched PKT group (ARR, −6.2 %; 95 % CI, −8.6 to −0.7; P = 0.03, and ARR, −6.7 %; 95 % CI, −9.6 to −0.7, P = 0.03, respectively); nevertheless, the corresponding ARRs were −3.2 % (95 % CI, −10.0 to 2.9; P = 0.44) and −2.2 % (95 % CI, −9.1 to 4.4; P = 0.72) after matching.

Conclusions

PKT was associated with neither improvement of post-transplant renal function nor a lower rate of common post-transplant complications than non-PKT among patients with end-stage renal disease who underwent living KT.
Literature
1.
go back to reference Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58(3):1311–7.CrossRefPubMed Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58(3):1311–7.CrossRefPubMed
2.
go back to reference Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med. 2001;344(10):726–31.CrossRefPubMed Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med. 2001;344(10):726–31.CrossRefPubMed
3.
go back to reference Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13(5):1358–64.CrossRefPubMed Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13(5):1358–64.CrossRefPubMed
4.
go back to reference Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int. 2006;69(10):1726–32.CrossRefPubMed Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int. 2006;69(10):1726–32.CrossRefPubMed
5.
go back to reference Ishani A, Ibrahim HN, Gilbertson D, et al. The impact of residual renal function on graft and patient survival rates in recipients of preemptive renal transplants. Am J Kidney Dis. 2003;42(6):1275–82.CrossRefPubMed Ishani A, Ibrahim HN, Gilbertson D, et al. The impact of residual renal function on graft and patient survival rates in recipients of preemptive renal transplants. Am J Kidney Dis. 2003;42(6):1275–82.CrossRefPubMed
6.
go back to reference Akkina SK, Connaire JJ, Snyder JJ, et al. Earlier is not necessarily better in preemptive kidney transplantation. Am J Transplant. 2008;8(10):2071–6.CrossRefPubMed Akkina SK, Connaire JJ, Snyder JJ, et al. Earlier is not necessarily better in preemptive kidney transplantation. Am J Transplant. 2008;8(10):2071–6.CrossRefPubMed
8.
go back to reference Huang Y, Samaniego M. Preemptive kidney transplantation: has it come of age? Nephrol Ther. 2012;8(6):428–32.CrossRefPubMed Huang Y, Samaniego M. Preemptive kidney transplantation: has it come of age? Nephrol Ther. 2012;8(6):428–32.CrossRefPubMed
9.
go back to reference Abramowicz D, Hazzan M, Maggiore U, et al. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. Nephrol Dial Transplant. 2016;31(5):691–7.CrossRefPubMed Abramowicz D, Hazzan M, Maggiore U, et al. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. Nephrol Dial Transplant. 2016;31(5):691–7.CrossRefPubMed
10.
go back to reference Okumi M, Unagami K, Tachibana H, et al. Association between body mass index and outcomes in Japanese living kidney transplant recipients: The role of sex differences. Int J Urol. 2016;23(9):776–8.CrossRefPubMed Okumi M, Unagami K, Tachibana H, et al. Association between body mass index and outcomes in Japanese living kidney transplant recipients: The role of sex differences. Int J Urol. 2016;23(9):776–8.CrossRefPubMed
11.
go back to reference Okumi M, Toki D, Nozaki T, et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transpl. 2016;16(3):886–96.CrossRef Okumi M, Toki D, Nozaki T, et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transpl. 2016;16(3):886–96.CrossRef
12.
go back to reference Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52(1):249–64.CrossRefPubMed Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52(1):249–64.CrossRefPubMed
13.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed
14.
go back to reference Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed
16.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed
17.
go back to reference Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873–90.CrossRefPubMed Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873–90.CrossRefPubMed
18.
go back to reference Friedewald JJ, Reese PP. The kidney-first initiative: what is the current status of preemptive transplantation? Adv Chronic Kidney Dis. 2012;19(4):252–6.CrossRefPubMedPubMedCentral Friedewald JJ, Reese PP. The kidney-first initiative: what is the current status of preemptive transplantation? Adv Chronic Kidney Dis. 2012;19(4):252–6.CrossRefPubMedPubMedCentral
19.
go back to reference Goto N, Okada M, Yamamoto T, et al. Association of dialysis duration with outcomes after transplantation in a japanese cohort. Clin J Am Soc Nephrol. 2016;11(3):497–504.CrossRefPubMedPubMedCentral Goto N, Okada M, Yamamoto T, et al. Association of dialysis duration with outcomes after transplantation in a japanese cohort. Clin J Am Soc Nephrol. 2016;11(3):497–504.CrossRefPubMedPubMedCentral
20.
go back to reference D’Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant. 2005;5(2):351–5.CrossRefPubMed D’Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant. 2005;5(2):351–5.CrossRefPubMed
21.
go back to reference Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166(1):44–8.CrossRefPubMed Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166(1):44–8.CrossRefPubMed
22.
go back to reference Gill JS, Tonelli M, Johnson N, et al. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation. 2004;78(6):873–9.CrossRefPubMed Gill JS, Tonelli M, Johnson N, et al. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation. 2004;78(6):873–9.CrossRefPubMed
23.
go back to reference Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609–19.CrossRefPubMed Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609–19.CrossRefPubMed
24.
go back to reference Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398–406.CrossRefPubMedPubMedCentral Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398–406.CrossRefPubMedPubMedCentral
25.
go back to reference Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–75.CrossRefPubMed Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–75.CrossRefPubMed
26.
go back to reference Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166–76.CrossRefPubMed Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166–76.CrossRefPubMed
27.
go back to reference Rostaing L, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–59.CrossRefPubMed Rostaing L, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–59.CrossRefPubMed
28.
go back to reference Kutner NG, Zhang R, Huang Y, et al. Impact of race on predialysis discussions and kidney transplant preemptive wait-listing. Am J Nephrol. 2012;35(4):305–11.CrossRefPubMedPubMedCentral Kutner NG, Zhang R, Huang Y, et al. Impact of race on predialysis discussions and kidney transplant preemptive wait-listing. Am J Nephrol. 2012;35(4):305–11.CrossRefPubMedPubMedCentral
29.
30.
go back to reference Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 Update: a Report From the American Heart Association. Circulation. 2016;133(4):e38–360.CrossRefPubMed Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 Update: a Report From the American Heart Association. Circulation. 2016;133(4):e38–360.CrossRefPubMed
31.
go back to reference Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270–7.CrossRefPubMed Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270–7.CrossRefPubMed
32.
go back to reference Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and ‘number needed to treat’. Kidney Int. 2007;72(7):789–91.CrossRefPubMed Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and ‘number needed to treat’. Kidney Int. 2007;72(7):789–91.CrossRefPubMed
33.
go back to reference Bock ME, Cohn RA. Pre-emptive kidney transplantation—just do it! Pediatr Transplant. 2010;14(5):561–4.CrossRefPubMed Bock ME, Cohn RA. Pre-emptive kidney transplantation—just do it! Pediatr Transplant. 2010;14(5):561–4.CrossRefPubMed
34.
go back to reference Weng FL, Mange KC. A comparison of persons who present for preemptive and nonpreemptive kidney transplantation. Am J Kidney Dis. 2003;42(5):1050–7.CrossRefPubMed Weng FL, Mange KC. A comparison of persons who present for preemptive and nonpreemptive kidney transplantation. Am J Kidney Dis. 2003;42(5):1050–7.CrossRefPubMed
35.
go back to reference Ferrari P, Weimar W, Johnson RJ, et al. Kidney paired donation: principles, protocols and programs. Nephrol Dial Transplant. 2015;30(8):1276–85.CrossRefPubMed Ferrari P, Weimar W, Johnson RJ, et al. Kidney paired donation: principles, protocols and programs. Nephrol Dial Transplant. 2015;30(8):1276–85.CrossRefPubMed
36.
go back to reference Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1–25.CrossRefPubMedPubMedCentral Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1–25.CrossRefPubMedPubMedCentral
37.
go back to reference Maggiore U, Oberbauer R, Pascual J, et al. Strategies to increase the donor pool and access to kidney transplantation: an international perspective. Nephrol Dial Transplant. 2015;30(2):217–22.CrossRefPubMed Maggiore U, Oberbauer R, Pascual J, et al. Strategies to increase the donor pool and access to kidney transplantation: an international perspective. Nephrol Dial Transplant. 2015;30(2):217–22.CrossRefPubMed
38.
go back to reference Andrews PA, Burnapp L, Manas D, et al. Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. Transplantation. 2012;93(7):666–73.CrossRefPubMed Andrews PA, Burnapp L, Manas D, et al. Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. Transplantation. 2012;93(7):666–73.CrossRefPubMed
39.
go back to reference Jay CL, Dean PG, Helmick RA, et al. Reassessing preemptive kidney transplantation in the United States: are we making progress? Transplantation. 2016;100(5):1120–7.CrossRefPubMedPubMedCentral Jay CL, Dean PG, Helmick RA, et al. Reassessing preemptive kidney transplantation in the United States: are we making progress? Transplantation. 2016;100(5):1120–7.CrossRefPubMedPubMedCentral
Metadata
Title
Preemptive kidney transplantation: a propensity score matched cohort study
Authors
Masayoshi Okumi
Yasuyuki Sato
Kohei Unagami
Toshihito Hirai
Hideki Ishida
Kazunari Tanabe
The Japan Academic Consortium of Kidney Transplantation (JACK)
Publication date
01-12-2017
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2017
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-016-1345-x

Other articles of this Issue 6/2017

Clinical and Experimental Nephrology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.